Squarepoint’s Disc Medicine IRON Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.03M Buy
31,709
+15,955
+101% +$1.11M ﹤0.01% 2171
2025
Q4
$1.25M Buy
15,754
+10,377
+193% +$877K ﹤0.01% 2418
2025
Q3
$355K Buy
+5,377
New +$320K ﹤0.01% 3535
2024
Q4
Sell
-8,805
Closed -$509K 5267
2024
Q3
$433K Buy
+8,805
New +$413K ﹤0.01% 3207
2024
Q1
Sell
-8,107
Closed -$468K 4286
2023
Q4
$468K Buy
8,107
+2,907
+56% +$149K ﹤0.01% 3055
2023
Q3
$244K Buy
+5,200
New +$260K ﹤0.01% 3292
2022
Q1
Sell
-494
Closed -$43K 3175
2021
Q4
$43K Buy
+494
New +$48.4K ﹤0.01% 3042

Other funds holding IRON

Squarepoint's IRON Position: Q1 2026 in Review

Squarepoint increased its Disc Medicine (IRON) stake by 101% in Q1 2026, buying an estimated $1.11M and bringing the position to 31,709 shares worth $2.03M. The position accounts for ﹤0.01% of the portfolio, ranked #2171.

Squarepoint first reported a position in IRON in Q4 2021 and has held it in 7 quarters since. 203 funds tracked by Wall St. Rank hold IRON as of Q1 2026.

  • Squarepoint held 31,709 shares of Disc Medicine worth $2.03M as of Q1 2026.
  • Squarepoint bought 15,955 Disc Medicine shares in Q1 2026, an estimated $1.11M.
  • Disc Medicine made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2171 holding.
  • Squarepoint first reported a position in Disc Medicine in Q4 2021 and has held it in 7 quarters since.
  • 203 funds tracked by Wall St. Rank held Disc Medicine as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.